david ettinger, md, talks about impact of immunotherapy in 1st line metastatic nsclc patients
Published 8 years ago • 26 plays • Length 0:35
Download video MP4
Download video MP3
Similar videos
-
0:25
david ettinger, md, on choosing between immunotherapy and chemotherapy in metastatic nsclc patients
-
1:32
david gandara, md, talks about the potential impact of immunotherapy in 1st line nsclc
-
0:47
david ettinger, md, talks about levels of pd-l1 expression and agent selection
-
1:11
david ettinger, md, provides practical advice related to pd-l1 testing in metastatic nsclc patients
-
0:56
david ettinger, md, on the positioning of ramucirumab (cyramza) for nsclc
-
0:41
julie brahmer, md, talks about the potential impact of immunotherapy in 1st line nsclc
-
0:35
david ettinger, md, on cost of therapy when choosing agents for late stage lung cancer patients
-
45:30
immunotherapy for brain cancer, with david reardon
-
0:46
david gandara, md, discusses considerations when choosing between immunotherapy and chemotherapy
-
2:09
dr. david carbone on the investigation of immunotherapy in lung cancer
-
45:36
patient to patient: what you need to know about cancer immunotherapy
-
33:11
brain cancer and immunotherapy with dr. david reardon
-
15:11
understanding cancer immunotherapy
-
2:53
immunotherapy: a revolution in cancer treatment
-
37:38
learn the basics of immunotherapy from david reardon, m.d.
-
54:21
cancer immunotherapy: where are we now? (2022)
-
26:02
doctors discuss: immunotherapy in lung cancer
-
35:07
the current role of immunotherapy in the treatment of patients with cancer
-
45:16
conversations about cancer immunotherapy: speaking with your oncologist
Clip.africa.com - Privacy-policy